Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev












Signal Accounts for Members
All Signal Accounts
All Contests



Australia Employment (Nov)A:--
F: --
Australia Full-time Employment (SA) (Nov)A:--
F: --
P: --
Australia Labor Force Participation Rate (SA) (Nov)A:--
F: --
P: --
Turkey Retail Sales YoY (Oct)A:--
F: --
P: --
South Africa Mining Output YoY (Oct)A:--
F: --
P: --
South Africa Gold Production YoY (Oct)A:--
F: --
P: --
Italy Quarterly Unemployment Rate (SA) (Q3)A:--
F: --
P: --
IEA Oil Market Report
Turkey 1-Week Repo RateA:--
F: --
P: --
South Africa Refinitiv/Ipsos Primary Consumer Sentiment Index (PCSI) (Dec)A:--
F: --
P: --
Turkey Overnight Lending Rate (O/N) (Dec)A:--
F: --
P: --
Turkey Late Liquidity Window Rate (LON) (Dec)A:--
F: --
P: --
U.K. Refinitiv/Ipsos Primary Consumer Sentiment Index (PCSI) (Dec)A:--
F: --
P: --
Brazil Retail Sales MoM (Oct)A:--
F: --
P: --
U.S. Weekly Continued Jobless Claims (SA)A:--
F: --
U.S. Exports (Sept)A:--
F: --
P: --
U.S. Trade Balance (Sept)A:--
F: --
U.S. Weekly Initial Jobless Claims (SA)A:--
F: --
Canada Imports (SA) (Sept)A:--
F: --
U.S. Initial Jobless Claims 4-Week Avg. (SA)A:--
F: --
P: --
Canada Trade Balance (SA) (Sept)A:--
F: --
Canada Exports (SA) (Sept)A:--
F: --
U.S. Wholesale Sales MoM (SA) (Sept)A:--
F: --
U.S. EIA Weekly Natural Gas Stocks ChangeA:--
F: --
P: --
China, Mainland M1 Money Supply YoY (Nov)--
F: --
P: --
China, Mainland M0 Money Supply YoY (Nov)--
F: --
P: --
China, Mainland M2 Money Supply YoY (Nov)--
F: --
P: --
U.S. 30-Year Bond Auction Avg. YieldA:--
F: --
P: --
Argentina CPI MoM (Nov)A:--
F: --
P: --
Argentina National CPI YoY (Nov)A:--
F: --
P: --
Argentina 12-Month CPI (Nov)--
F: --
P: --
U.S. Weekly Treasuries Held by Foreign Central Banks--
F: --
P: --
Japan Industrial Output Final MoM (Oct)--
F: --
P: --
Japan Industrial Output Final YoY (Oct)--
F: --
P: --
U.K. Services Index MoM (SA) (Oct)--
F: --
P: --
U.K. Services Index YoY (Oct)--
F: --
P: --
Germany HICP Final YoY (Nov)--
F: --
P: --
Germany HICP Final MoM (Nov)--
F: --
P: --
U.K. Trade Balance Non-EU (SA) (Oct)--
F: --
P: --
U.K. Trade Balance (Oct)--
F: --
P: --
U.K. Services Index MoM--
F: --
P: --
U.K. Construction Output MoM (SA) (Oct)--
F: --
P: --
U.K. Industrial Output YoY (Oct)--
F: --
P: --
U.K. Trade Balance (SA) (Oct)--
F: --
P: --
U.K. Trade Balance EU (SA) (Oct)--
F: --
P: --
U.K. Manufacturing Output YoY (Oct)--
F: --
P: --
U.K. GDP MoM (Oct)--
F: --
P: --
U.K. GDP YoY (SA) (Oct)--
F: --
P: --
U.K. Industrial Output MoM (Oct)--
F: --
P: --
U.K. Manufacturing Output MoM (Oct)--
F: --
P: --
U.K. Monthly GDP 3M/3M Change (Oct)--
F: --
P: --
Germany CPI Final MoM (Nov)--
F: --
P: --
Germany CPI Final YoY (Nov)--
F: --
P: --
U.K. Construction Output YoY (Oct)--
F: --
P: --
France HICP Final MoM (Nov)--
F: --
P: --
China, Mainland Outstanding Loans Growth YoY (Nov)--
F: --
P: --
U.K. Inflation Rate Expectations--
F: --
P: --
India CPI YoY (Nov)--
F: --
P: --
India Deposit Gowth YoY--
F: --
P: --


No matching data
Latest Views
Latest Views
Trending Topics
Top Columnists
Latest Update
White Label
Data API
Web Plug-ins
Affiliate Program
View All

No data
Q3 revenue grew 1.53% year-over-year, signaling a turnaround, while YTD net profit fell 28.83%. International business drove growth, especially in Europe, offsetting domestic market contraction. R&D investment remained high and dividend payouts continued.
Original document: Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A [300760] Interim report — Oct. 30 2025
Revenue fell 18.45% and net profit dropped 32.96% year-over-year in H1 2025, with international business now half of total revenue and showing growth, while domestic sales declined. The company expects a return to growth in Q3, continues strong R&D investment, and maintains a high dividend payout.
Original document: Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A [300760] Interim report — Aug. 28 2025
Shenzhen Mindray Bio-Medical Electronics has an average rating of buy and mean price target of 294.27 yuan, according to analysts polled by FactSet.
WuXi AppTec Chairman Li Ge was China's highest-paid chairperson among A-listed companies in 2024, Yicai Global reported, citing data from Wind Information.
Li's pre-tax annual pay was at 41.8 million yuan, the report said.
Mindray Bio-Medical Electronics Chairman Li Xiting came in second with 24.9 million yuan in annual pre-tax pay, and John Oyler of BeiGene is third with 20.2 million yuan, the report said.
A total of 13 chairpersons from Chinese-listed firms had annual pay of more than 10 million yuan in 2024, the report said.
In total, listed companies paid 5.8 billion yuan to chairpersons, Yicai said.
Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.
Shenzhen Mindray Bio-Medical Electronics has an average rating of buy and mean price target of 307.25 yuan, according to analysts polled by FactSet.
Mindray achieved 5.14% revenue growth and 0.74% net profit growth in 2024, with international business up 21.28% and a major expansion into cardiovascular devices via the Huatai Medical acquisition. R&D investment reached 10.91% of revenue, and the company maintained a 65.15% dividend payout.
Original document: Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A [300760] Annual Financial Statement — Apr. 29 2025
Q1 2025 revenue and net profit declined year-over-year, but international business grew and domestic business rebounded sequentially. R&D investment remained high, and the company expects a domestic recovery from Q3 2025.
Original document: Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A [300760] Interim report — Apr. 29 2025
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features

FastBull Membership
Not yet
Purchase
Log In
Sign Up